Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Bulletin of the National Research Centre. 2006; 31 (3): 209-219
in English | IMEMR | ID: emr-197745

ABSTRACT

vinpocetine is a widely used drug for the treatment of cerebrovascular and memory disorders. This study aimed to investigate the effect of vinpocetinc on the acute hepatic injury caused in the rat by the administration of CCl[4] in viva. Vinpocetine [2.1, 4.2, 8.4 mg/kg] or silymarin [30 mg/kg] was given once daily orally simultaneously with CCl[4] and for 15 days thereafter. Liver damage was assessed by determining serum enzyme activities and hepatic histopathology. Stained sections were subjected to morphometric evaluation using computerized image analyzer. The results showed that vinpocetine administered to CCl[4]-treated rats decreased the elevated alanine aminotransferase [ALT] by 49.3, 58.] and 63.6%, aspartate aminotransferase [AST] by 10.5, 22.6 and 27.2% and alkaline phosphatase [ALP] by 52.5, 59.6 and 64.9%, respectively and in a dose-dependent manner. Meanwhile, silymarin reduced elevated ALT, AST and ALP levels by 53.1, 26.9 and 66%, respectively. Histological examination of liver specimens revealed a marked reduction in liver cell necrosis in vinpocetine and silymarin- treated rats compared with vehicle-treated CCl[4]-treated rats. Quantitative analysis of the area of damage showed 85.3% reduction in the area of damage after silymarin and 72.2, 78.9 and 85.3% reduction after vinpocetine treatment at 2.1, 4.2, 8.4 mg/kg, respectively. It is concluded that administration of vinpocetine in a model of CCl4-induced liver injury in rats resulted in reduction of liver damage. The reduction obtained by 4.2 mg/kg of vinpocetine was similar to that obtained by 30 mg/kg silymarin. Therefore, it is suggested that vinpocetine might be a good pharmacological agent in the treatment of liver disease besides its neuroprotective effects

SELECTION OF CITATIONS
SEARCH DETAIL